They include studies on molecular virology and cell biology of HIV infection, immunology and pathogenesis of HIV and related retroviruses, discovery, design and evaluation of non-immunological therapeutics, and development and delivery of HIV vaccines. Also, included are basic science, pre-clinical and clinical studies of the pathogenesis of HIV/AIDS associated pathogens and cancers, co-infection with other infectious disease and co-morbidities associated with chronic infections of HIV. Behavioral and social science applications at the individual level as well as those addressing epidemiologic, population-based, and health services approaches involving HIV prevention and care for those living with HIV/AIDS are also reviewed in the AARR IRG.
- HIV Coinfections and HIV Associated Cancers HCAC
- HIV Comorbidities and Clinical Studies HCCS
- HIV Immunopathogenesis and Vaccine Development HIVD
- HIV Molecular Virology, Cell Biology, and Drug Development HVCD
- HIV/AIDS Intra- and Inter-personal Determinants and Behavioral Interventions HIBI
- Population and Public Health Approaches to HIV/AIDS PPAH
- HIV/AIDS Fellowship Special Emphasis Panels (AARR Fellowship SEP) F17
- HIV/AIDS Small Business Applications: AARR Small Business Special Emphasis Panels (AARR Small Business SEPs) AARR (10)
- HIV/AIDS Small Business Applications: AARR Small Business Special Emphasis Panels AARR (11)
- All AIDS-related grant applications are reviewed on an expedited cycle as mandated by Congress, and are therefore reviewed by one of the study sections or by Special Emphasis Panels within the AARR IRG.
- For applications to be eligible for expedited review they must address research goals that are relevant to HIV/AIDS. Applications focusing on opportunistic pathogens and cancers must make a clear connection between the goals of their study and AIDS.
- AIDS-related applications that may be appropriate for review by another CSR study sections are not referred there due to the differences in the receipt and review dates within the review cycle.